Esker And 2 Other High Growth Tech Stocks In France

In the midst of a challenging environment for global markets, with France's CAC 40 Index dropping 3.65% amid renewed fears about economic growth, it's crucial to identify high-growth opportunities in resilient sectors like technology. Despite broader market declines, companies that demonstrate strong innovation and robust growth potential can offer compelling investment prospects.

Top 10 High Growth Tech Companies In France

Name	Revenue Growth	Earnings Growth	Growth Rating
Icape Holding	12.59%	27.33%	★★★★★☆
Cogelec	11.33%	23.96%	★★★★★☆
VusionGroup	21.32%	25.74%	★★★★★★
Munic	26.68%	149.10%	★★★★★☆
Adocia	59.08%	63.00%	★★★★★★
Oncodesign Société Anonyme	14.68%	101.18%	★★★★★☆
Valneva	24.22%	28.34%	★★★★★☆
beaconsmind	28.59%	133.36%	★★★★★★
Pherecydes Pharma Société anonyme	63.30%	78.85%	★★★★★☆
OSE Immunotherapeutics	30.02%	5.91%	★★★★★☆

Click here to see the full list of 45 stocks from our Euronext Paris High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Esker (ENXTPA:ALESK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Esker SA operates a cloud platform for finance and customer service professionals in France and internationally, with a market cap of €1.37 billion.

Operations: Esker SA generates revenue primarily from its Software & Programming segment, which accounted for €190.92 million. The company serves finance and customer service professionals through its cloud platform across various regions.

Esker, a prominent player in the French tech landscape, has shown a robust revenue growth forecast of 11% annually, outpacing the broader French market's 5.7%. With earnings projected to surge by 25.9% per year and an anticipated return on equity of 20.1%, Esker demonstrates significant potential. The company's commitment to innovation is evident from its recent enhancements to the Source-to-Pay suite, integrating ESG metrics and sustainability features that align with evolving regulatory frameworks. Notably, Esker's R&D expenses have consistently supported these advancements, ensuring continued competitiveness in the dynamic software sector.

• Click to explore a detailed breakdown of our findings in Esker's health report.

• Evaluate Esker's historical performance by accessing our past performance report.

CS Communication & Systemes (ENXTPA:SX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CS Communication & Systemes SA designs, integrates, and operates mission-critical systems worldwide with a market cap of €281.82 million.

Operations: The company specializes in designing, integrating, and operating mission-critical systems globally. It generates revenue primarily through these services.

CS Communication & Systemes (CS) is making strides in the tech sector with a forecasted revenue growth of 10.4% annually, outpacing the broader French market's 5%. Despite current unprofitability, earnings are expected to surge by 88.23% per year over the next three years. The company has significantly invested in R&D, dedicating €24M last year to drive innovation and maintain competitiveness. Notably, CS serves high-profile clients like Airbus and Thales, positioning itself well for future growth within the defense and aerospace sectors.

• Take a closer look at CS Communication & Systemes' potential here in our health report.

• Explore historical data to track CS Communication & Systemes' performance over time in our Past section.

Valneva (ENXTPA:VLA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Valneva SE, a specialty vaccine company, focuses on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet needs and has a market cap of €428.59 million.

Operations: Valneva SE generates revenue primarily through the development and commercialization of prophylactic vaccines, with a reported revenue of €156.47 million. The company specializes in addressing infectious diseases that have unmet medical needs.

Valneva's revenue is projected to grow at 24.2% annually, significantly outpacing the French market's 5.7%. The company's recent partnership with Pfizer for the VLA15 Lyme disease vaccine and its strategic licensing agreement with LimmaTech for Shigella4V highlight its robust R&D efforts, which saw an investment of €28M last year. Additionally, Valneva reported a net income of €33.98M for H1 2024, a notable turnaround from a net loss of €35.05M in H1 2023.

• Click here to discover the nuances of Valneva with our detailed analytical health report.

• Gain insights into Valneva's historical performance by reviewing our past performance report.

Make It Happen

• Embark on your investment journey to our 45 Euronext Paris High Growth Tech and AI Stocks selection here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com